Bank of America
CNTX icon

Bank of America’s Context Therapeutics CNTX Stock Holding History

Bank of America’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$301K Buy
114,888
+113,955
+12,214% +$266K ﹤0.01% 5151
2025
Q4 		$1.37K Buy
933
+499
+115% +$583 ﹤0.01% 6442
2025
Q3 		$420 Sell
434
-109
-20% -$88 ﹤0.01% 7618
2025
Q2 		$356 Buy
543
+99
+22% +$71 ﹤0.01% 7726
2025
Q1 		$272 Sell
444
-5,813
-93% -$5.06K ﹤0.01% 7628
2024
Q4 		$6.57K Sell
6,257
-3,935
-39% -$6.81K ﹤0.01% 7055
2024
Q3 		$20K Sell
10,192
-584
-5% -$1.29K ﹤0.01% 6740
2024
Q2 		$21.6K Buy
+10,776
New +$18.6K ﹤0.01% 6724
2024
Q1 		– Sell
-109
Closed -$123 – 7791
2023
Q4 		$123 Buy
109
+9
+9% +$10 ﹤0.01% 7393
2023
Q3 		$151 Hold
100
– – ﹤0.01% 7434
2023
Q2 		$160 Hold
100
– – ﹤0.01% 7395
2023
Q1 		$56 Sell
100
-17
-15% -$13 ﹤0.01% 7514
2022
Q4 		$76 Buy
+117
New +$126 ﹤0.01% 7720

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bank of America's CNTX Position: Q1 2026 in Review

Bank of America increased its Context Therapeutics (CNTX) stake by 12,214% in Q1 2026, buying an estimated $266K and bringing the position to 114,888 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #5151.

Bank of America first reported a position in CNTX in Q4 2022 and has held it in 13 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Bank of America held 114,888 shares of Context Therapeutics worth $301K as of Q1 2026.
  • Bank of America bought 113,955 Context Therapeutics shares in Q1 2026, an estimated $266K.
  • Context Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5151 holding.
  • Bank of America first reported a position in Context Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.